Spinal muscular atrophy (SMA), the leading genetic cause of infant mortality, is caused by the loss of the survival motor neuron-1 (SMN1) gene, which leads to motor neuron loss, muscle atrophy, respiratory distress, and death. Motor neurons exhibit the most profound loss, but the mechanisms underlying disease pathogenesis are not fully understood. Recent evidence suggests that motor neuron extrinsic influences, such as those arising from astrocytes, contribute to motor neuron malfunction and loss. Here we investigated both loss-of-function and toxic gain-of-function astrocyte mechanisms that could play a role in SMA pathology. We had previously found that glial derived neurotrophic factor (GDNF) is reduced in SMA astrocytes. However, reduced GDNF expression does not play a major role in SMA pathology as viral-mediated GDNF re-expression did not improve astrocyte function or motor neuron loss. In contrast, we found that SMA astrocytes increased microRNA (miR) production and secretion compared to control astrocytes, suggesting potential toxic gain-of-function properties. Specifically, we found that miR-146a was significantly upregulated in SMA induced pluripotent stem cell (iPSC)-derived astrocytes and SMND7 mouse spinal cord. Moreover, increased miR-146a was sufficient to induce motor neuron loss in vitro, whereas miR146a inhibition prevented SMA astrocyte-induced motor neuron loss. Together, these data indicate that altered astrocyte production of miR-146a may be a contributing factor in astrocyte-mediated SMA pathology.
Introduction
Spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality. SMA is caused by the homozygous deletion or disruption of the survival motor neuron-1 (SMN1) gene, which leads to motor neuron loss, muscle atrophy, respiratory distress, and death (1) . Humans have two copies of SMN: a telomeric copy (SMN1) and a centromeric copy (SMN2) (2) . SMN1 produces a full-length SMN protein found in both the cytoplasm and the nucleus with functions relating to biogenesis of RNA proteins, RNA transcription, pre-mRNA splicing, and mRNA transport (3) (4) (5) (6) . In contrast, SMN2 produces a truncated, mostly non-functional SMN protein due to an alternative splicing event deleting exon 7 (7) (8) (9) (10) .
Astrocytes, the most abundant cell type in the central nervous system, are integral components of a normally functioning neural circuit. Healthy astrocytes maintain the blood-brain barrier, provide trophic support to surrounding cells, maintain extracellular ion balance, secrete molecules necessary for neuronal energy and metabolism, and take up and recycle neurotransmitters (11) . Stress and injury can cause resting astrocytes to become reactive, which alters astrocyte morphology, increases intermediate filament protein expression, reduces trophic support, reduces extracellular glutamate uptake, changes ion buffering properties, promotes glial scar formation, and increases proinflammatory cytokine production (12) (13) (14) (15) (16) . Reactive astrocytes have been shown to be involved in the disease pathology of a number of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease (17) (18) (19) (20) (21) . We have previously demonstrated astrocyte activation prior to overt motor neuron loss in both in vivo and in vitro models of SMA (22, 23) , that reactive astrocytes can induce otherwise healthy astrocytes to adopt a reactive phenotype (23) , and have recently validated the astrocyte contribution to SMA pathology in vivo (24) . However, the potential feed-forward mechanism by which SMA astrocytes contribute to motor neuron damage and decline has not been fully elucidated.
A number of astrocyte-produced factors impact motor neuron health and development, including glial fibrillary acidic protein (GFAP), the pro-peptide version of nerve growth factor, and various cytokines including tumor necrosis factor alpha (TNFa) and interleukin (IL) 1b (25) (26) (27) (28) . MicroRNAs (miRs), which are short non-coding RNAs that post-transcriptionally repress protein targets by pairing with the 3' untranslated region of the target mRNA, are another potential contributor to astrocytemediated neuronal damage (29) . For example, astrocyte secreted miR-34a increases vulnerability of dopaminergic neurons to stress (30) . miR-181 and miR-29 family members are enriched in astrocytes (31, 32) and have been shown to directly influence the expression of inflammatory and apoptotic mediators (32) , with apoptosis being particularly relevant to motor neuron loss in SMA (33) (34) (35) . In the context of SMA, a small number of potential disease-relevant miRs have been identified, including miR-9, miR-100, miR-335, miR-375, and miR-431 (36) (37) (38) (39) (40) . However, none of these reports address miR expression and production specifically in SMA astrocytes.
Here, we examined induced pluripotent stem cell (iPSC)-derived astrocytes and found that SMA astrocytes have increased production and secretion of miR-146a as compared to control. Others have reported that miR-146a is upregulated in mouse and marmoset astrocyte cultures activated by treatment with lipopolysaccharide (41) as well as in human primary astrocytes stressed with metal sulfate (42) . Additionally, astrocyte up-regulation of miR-146a has been reported in temporal lobe epilepsy and in Alzheimer's disease (43, 44) . miR-146a is involved in modulating the immune system in response to interleukins and TNFa production. In this regard, we have previously found that spinal cords from SMND7 mice and SMA patients have increased mRNA levels of IL-1b, IL-6, and TNFa (24) . Consistent with these data, here we report that miR-146a is significantly increased in SMND7 mouse spinal cord. Treating iPSC-derived motor neurons with synthesized miR-146a molecules is sufficient to induce significant motor neuron loss. Moreover, motor neurons loss induced by SMA astrocyte conditioned medium is significantly blocked by a miR-146a inhibitor. Together, these data indicate that astrocyte upregulation of miR-146a may be a potential mechanism for astrocyte-mediated SMA motor neuron pathology.
Results
Previous studies from our lab and others demonstrated that SMA iPSC-derived motor neurons undergo selective loss in culture (34, 45) . However, these cultures are not homogeneous as they contain a mixture of neurons, motor neurons, and astrocytes. The cellular complexity of these cultures has made the identification of intrinsic and extrinsic disease mechanisms exceedingly difficult. Therefore, with the development of techniques to significantly improve motor neuron purity (46), we tested whether purified SMA iPSC-derived motor neurons grown in the absence of astrocytes exhibit greater loss over time compared to control motor neurons. We followed the protocol established by Maury and colleagues (46) and found robust motor neuron differentiation using the motor neuron markers islet1 and ChAT immunostaining, and negligible GFAPþ astrocyte generation, in SMA and control cultures (Fig. 1A and B) with no difference in ChATþ motor neuron number at 28 days of differentiation under basal conditions (Fig. 1E) . These data are in contrast to results from mixed motor neuron/astrocyte cultures (34, 45) , but are consistent with purified primary motor neuron cultures derived from severe SMA mouse spinal cord (47) . Therefore, these data indicate that intrinsic SMA motor neuron deficits may not be sufficient to induce significant human motor neuron loss, even out to 42 days of differentiation (Fig. 1F ) and suggest that non-cell autonomous influences from SMA astrocytes negatively impact motor neuron health. Consistent with this notion, culturing purified motor neurons from either control or SMA iPSCs with SMA iPSC-derived astrocyte conditioned medium (ACM) induces significant loss of ChATþ motor neurons, and many of the neurons that remained lacked neurite projections ( Fig. 1C-E) . Importantly, culture with control iPSC-derived ACM did not significantly reduce ChATþ motor neuron number (Fig. 1E ). These data indicate that the SMA astrocyte secretome is sufficiently altered to impede motor neuron survival.
We next aimed to examine the mechanisms that could underlie astrocyte-mediated motor neuron loss. We previously found that SMA iPSC-derived astrocytes exhibit reduced glial derived neurotrophic factor (GDNF) expression (22) . We first asked whether features of astrocyte reactivity, such as altered morphology and reduced calcium signaling could be rescued with GDNF re-expression. A lentivirus expressing GDNF or a GFP control was administered to SMA iPSC-derived astrocytes, resulting in a significant increase in GDNF protein production in the GDNF infected cells compared to uninfected SMA cells; lentiGFP infection did not increase GDNF protein levels (Supplementary Material, Fig. S1A ). However, in contrast to our previous data showing morphological and survival benefits provided by re-expression of SMN (23, 24) , GDNF re-expression did not affect GFAPþ astrocyte projection length (Supplementary Material, Fig. S1B ) or calcium-signaling response to ATP stimulation (Supplementary Material, Fig. S1C ). Similarly, lentiGDNF had no survival benefit for SMI-32þ/Tuj1þ SMA iPSC-derived motor neurons in the mixed astrocyte-motor neuron culture conditions (Supplementary Material, Fig. S1D ). These results suggest that diminished GDNF production and secretion from SMA astrocytes is not a significant contributor to SMA motor neuron loss.
We next examined possible toxic gain-of-function mechanisms in SMA astrocytes that could promote motor neuron loss. Recent studies have shown that astrocyte-produced miRs can play an important role in neuronal damage (29, 30) and that a small number of miRs are misregulated in SMA mouse and human motor neurons (36) (37) (38) (39) (40) . In contrast, miR misregulation in astrocytes has not been determined. Therefore, astrocyte cell lysates were examined for miR expression using PCR arrays assessing 84 of the most abundantly expressed and well characterized human miRs. SMA iPSC astrocytes had 5 differentially expressed miRs that were upregulated or downregulated at least 2-fold compared to healthy control astrocytes across multiple iPSC lines and independent experiments ( Fig. 2A) . Of the upregulated miRs, miR-146a had the greatest increase in SMA iPSC-derived astrocytes ( Fig. 2A, 7 .47 fold increase, P ¼ 0.0419), which was further confirmed by qRT-PCR ( Fig.  2B , P ¼ 0.0267). As a measure of astrocyte differentiation quality control, miR-181a, known to be enriched in normal astrocytes (32), was not among the differentially expressed miRs (Supplementary Material, Table S1 ). As miRs are known to be packaged and secreted in small multivesicular exosomes (48), we examined whether control and SMA iPSC-derived ACM contained these small nanoparticles. Using a NanoSight particle counter, we found that ACM from both control and SMA iPSCderived astrocyte cultures contained particles in the 30-100 nm range predictive of exosomes (Fig. 2C) . Next we isolated exosomes from ACM using commercially available isolation kits and high-speed centrifugation and probed for miR expression using the miR PCR arrays. We found that 7 miRs were differentially expressed in exosomes from SMA iPSC-derived ACM compared to control ACM-derived exosomes (Fig. 2D ). miR-146a was again highly upregulated in isolated exosomes from SMA iPSCderived ACM (Fig. 2D, 6 .8 fold increase, P ¼ 0.01715) and was the only miR found to be upregulated in both SMA astrocyte cell pellets and isolated exosomes. We have previously shown that astrocyte malfunction is largely mitigated by re-expression of SMN (23, 24) . Similarly, we found that miR-146a expression was returned to near control levels in SMA iPSC-derived astrocytes re-expressing SMN and in the associated isolated exosomes (Supplementary Material, Fig. S2A and B). We next assessed miR-146a levels in vivo using the relatively severe SMND7
) mouse model (49), a wellcharacterized SMA mouse model that is extensively used for biological and translational studies (22, 24, (50) (51) (52) (53) . Importantly, qRT-PCR analysis revealed that the longer primary transcript for miR-146a, pri-miR-146a, was upregulated $18-fold in postnatal day 12 SMND7 mouse spinal cord compared to control mice ( Fig. 3A , P ¼ 0.00095), and the mature miR-146a was upregulated $2 fold ( Fig. 3B , P ¼ 0.03384). These data suggest that miR-146a may participate in SMA disease pathology. miR-146a is known to be activated downstream of cytokine production and toll-like receptor mediated signaling pathways culminating in NFjB transcription and subsequent upregulation of other immune-responsive genes. miR-146a is known to be directly regulated by NFjB likely as a means to regulate innate immunity and the adaptive immune response (54). We have found that spinal cords from SMND7 mice and SMA patients have increased expression of IL-1b, IL-6, and TNFa (24) and significant upregulation of ERK1/2 activation, a known inducer of NFjB signaling (55) in SMA iPSC-derived astrocytes compared to control astrocytes (22) . Therefore, we used immunocytochemistry to examine expression and cellular localization of total and phosphorylated NFjB in iPSC-derived astrocyte cultures (Fig. 4A ). We observed a robust increase in NFjB expression and nuclear localization of phospho-NFjB in SMA iPSC-derived astrocytes whereas there was only minimal NFjB expression observed in control astrocytes ( Fig. 4B-D) . Additionally, a recent study identified the transcription factor GATA6, which is known to be involved in organogenesis (56, 57) , as a novel SMN target; GATA6 levels were significantly increased in SMA mouse and human samples, and the increase positively correlated with disease severity (58) . Consistent with these data, we observed a nearly 9-fold increase in GATA6 transcript by qRT-PCR in SMA astrocytes ( Fig. 5A ) that corresponded to a significant increase in GATA6 protein compared to control astrocytes ( Fig. 5B , P ¼ 0.0136). Synergistic interactions between GATA6 and NFjB (59) point to additional mechanistic links contributing to miR-146a expression, which may ultimately result in motor neuron loss. Next, we tested whether miR-146a alone was sufficient to induce motor neuron loss in the iPSC system. Using purified motor neuron cultures, we treated SMA and control iPSC motor neurons with a synthetic miRNA corresponding to the endogenous miR-146a sequence and counted the number of ChATþ motor neurons remaining 48 h following treatment. Compared to a scrambled miR control, miR-146a induced significant loss of both control and SMA motor neurons (Fig. 6A) . Finally, we tested whether miR-146a contributed to the motor neuron loss induced by SMA ACM (Fig. 1) . Both control and SMA iPSC-derived motor neurons were significantly protected from SMA ACM-induced toxicity in the presence of a miR-146a inhibitor (Fig. 6B) , but a scrambled miR-inhibitor control did not improve motor neuron survival or retain neurite projections. Taken together, these data suggest that astrocyte-derived miR146a production and secretion may be a potential contributor to SMA pathogenesis.
In an effort to determine potential mechanisms underlying astrocyte-mediated motor neuron loss, we used a miR-146a downstream target qRT-PCR array to examine gene changes in control iPSC-derived motor neurons treated with SMA ACM. However, none of the downstream target genes were changed more than two fold and none reached significance (data not shown). NOTCH, which is intimately involved in neuron development, synaptic plasticity, and neuron survival (60), was a potentially interesting miR-146a target because a previous report had found that NOTCH expression was significantly increased in SMN knockdown cell lines and SMND7 spinal cord astrocytes and motor neurons (61), whereas another report indicated decreased NOTCH transcript in SMN deficient mouse embryonic stem cell-derived motor neurons (62) . However, we were unable to detect significant differences in protein expression for either NOTCH 1 or NOTCH 2 in control and SMA iPSC-derived motor neurons, even in the presence of SMA ACM (data not shown).
Discussion
The mechanisms underlying the relatively selective motor neuron loss in SMA is currently unknown. However, recent evidence suggests the involvement of non-cell autonomous factors that can influence SMA pathology. For example, replacing SMN using the motor neuron specific promotor HB9 in SMA mouse models modestly improved motor neuron survival and disease outcome (63), whereas SMN replacement using broad neural expression with the prion promotor provided robust benefit (64) . The contribution of other cell types to SMA motor neuron loss is clearly supported by in vitro data using purified motor neuron cultures. Early work showed that cultures of isolated mouse SMA spinal cord motor neurons did not die in vitro (47) . These results were in contrast to our early work with human iPSCderived motor neuron cultures in which we showed clear loss of the motor neuron population in vitro by 6 weeks in culture (34, 45) . We initially postulated that there could be speciesspecific differences that were sufficient to induce motor neuron loss in human motor neurons compared to mouse. However, in light of the data presented here showing a lack of motor neuron loss in SMA iPSC-derived motor neuron cultures devoid of astrocytes (Fig. 1) , our previous results were likely due to the mixed neuron-astrocyte composition of the culture (34, 45) . Moreover, our more recent work has demonstrated that astrocyte-specific replacement of SMN is sufficient to extend lifespan and mitigate motor functional loss in SMA mice (24) . Together, these data indicate that the complex pathogenic picture of SMA extends beyond the motor neuron.
Over the past few years, we have found phenotypic changes in SMA astrocytes, such as altered morphology, altered signaling, and decreased growth factor production (22, 23) , that could negatively impact motor neuron health. Here, we show that conditioned medium from SMA iPSC-derived astrocytes is sufficient to induce loss of both healthy and SMA iPSC-derived motor neurons (Fig. 1) . We next examined potential loss-offunction or toxic gain-of-function mechanisms involved in SMA astrocyte-mediated motor neuron damage in order to investigate the mechanisms underlying the non-cell autonomous effect of astrocytes on motor neurons. Consistent with this idea, a very recent study identified a significant downregulation of MCP1 in SMA mouse spinal cord astrocytes contributing to reduced motor neuron neurite outgrowth (65) . Considering that the astrocyte secretome contains a myriad of factors (66) and large-scale proteomic analysis of conditioned medium from mouse primary astrocyte cultures identified nearly 6000 unique protein groups (66), we focused on the previously identified candidates GDNF (22) and miRs (29, 30) .
The lack of GDNF expression in SMA astrocytes was an intriguing loss-of-function mechanism as GDNF is known to be a potent survival factor for a number of neuronal subtypes (67, 68) . As such, exogenous GDNF expression is a promising treatment for a number of neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis (69) (70) (71) (72) , and the therapeutic benefit of GDNF gene therapy is currently being investigated clinically for both diseases. Therefore, it was surprising that GDNF re-expression did not decrease astrocyte reactivity (Supplementary Material, Fig. S1 ) or promote motor neuron survival (Supplementary Material, Fig. S1 ) in the SMA iPSC model. We have previously shown that SMA iPSC-derived motor neurons undergo caspase-dependent apoptotic cell death (34), but we cannot rule out the possibility that SMA iPSC-derived motor neurons fail to develop in the mixed culture condition. Regardless, restoring GDNF expression did not have a positive benefit. It is possible that we had saturated the culture conditions (67) such that additional GDNF was not beneficial in vitro. GDNF re-expression may still be beneficial in in vivo SMA models as GDNF can also inhibit microglial activation (73) . Reactive microglia have been observed in SMND7 mouse spinal cord where they have been shown to phagocytose degenerating presynaptic motor neuron terminals (74) . Therefore, GDNF re-expression could reverse microglial activation, dampen microglial secretion of pro-inflammatory cytokines, and may influence overall function of astrocytes and motor neurons to confer survival benefit to the whole animal.
In recent years, miRs have emerged as important contributors to neurodegeneration (29) and are known to be secreted from astrocytes. For example, astrocyte secreted miR-34a increases vulnerability of dopamine neurons to stress (30) , whereas astrocyte produced miR-181 and miR-29 family members (31, 32) , are known to have direct influence on the expression of inflammatory and apoptotic mediators (32) . Therefore, we analysed the miR expression and secretory profile in SMA astrocytes to investigate a potential toxic contribution to motor neuron loss. The miRs that have been identified in the context of SMA, including miR-9, miR-100, miR-335, miR-375, and miR-431, have focused on motor neuron-specific properties, such as neurogenesis and axon outgrowth (36) (37) (38) (39) (40) . In the current study, we found miR-146a to be the only miR that was highly and significantly upregulated in both SMA astrocytes and the secreted exosomes (Fig. 2) . As important confirmation, we found miR146a to be significantly upregulated in SMND7 mouse spinal cord (Fig. 3) , which is consistent with astrocyte upregulation of miR-146a in other stress and disease conditions (41) (42) (43) (44) 75) . Moreover, our data showed that exogenously applied miR-146a was sufficient to induce motor neuron loss in purified control and SMA motor neuron cultures (Fig. 6) , which further supports the idea of astrocyte-mediated SMA pathology. miR-146a is involved in modulating the immune system in response to interleukins, TNFa, and glial activation (54, 76) , which is consistent with the upregulation IL-1b, IL-6, and TNFa in spinal cords from SMND7 mice and SMA patients (24) . Simultaneously, excessive production of miR-146a from SMA astrocytes may cause downregulation of critical signaling pathways in motor neurons and thereby contribute to motor neuron decline. In this regard, miR146a is known to downregulate GDNF at both the transcript and protein levels (77) , which may contribute to the lack of benefit from GDNF re-expression in this system (Supplementary Material, Fig. S1 ), particularly in the absence of additional miR146a inhibition. Alternatively, downregulation of miR-146a target genes may negatively impact motor neuron health and function. NOTCH2 is a potentially interesting miR-146a downstream target due to the important role of NOTCH signaling in neuron development, health, and function. Human embryonic stem cell derived motor neurons have been shown to express equivalent levels of NOTCH1, NOTCH2, and NOTCH3 (78), and a previous study in Drosophila found that NOTCH expression was predominantly in the cell bodies of presynaptic motor neuron neurons, was positively correlated with motor neuron activity, and was required for neuromuscular junction strength and plasticity (79) . Although we did not find a significant change in NOTCH2 transcript or protein levels in control motor neurons treated with SMA ACM (data not shown), it is possible that subtle changes in NOTCH and other downstream targets synergize to elicit the motor neuron phenotype. However, much more research is needed to elucidate the specific molecular mechanisms and gene expression changes underlying the effect of astrocyte-derived miR-146a in motor neuron loss.
How miR-146a is upregulated in astrocytes is a question that still needs to be addressed. We have shown previously that astrocyte SMN re-expression reverses astrocyte malfunction and can extend lifespan in SMA mice (23, 24) . Here, we found that SMN re-expression decreased miR-146a expression back to near control levels (Supplementary Material, Fig. S2 ), suggesting miR146a misregulation is either directly or indirectly linked to SMN levels. One potential mechanism linking SMN and miR-146a is through GATA transcription factors. GATA factors are zinc finger transcription factors required for organogenesis (56, 57) , and one recent study identified GATA6 as being negatively regulated by SMN such that GATA6 transcript levels were significantly increased in SMA mouse and human samples and correlated with disease severity (58) . Consistent with these data, we found a significant increase in GATA6 transcript and protein levels in the SMA iPSC-derived astrocytes compared to control (Fig. 5) . NFjB is a known inducer of miR-146a (54), and synergistic interactions between GATA6 and NFjB (59) could lead to activation miR-146a, which is consistent with an upregulation of NFjB in the SMA iPSC-derived astrocytes (Fig. 4) . Regulation of miR-146a activation may vary from cell to cell, so more work is needed to definitively determine the SMN-mediated signaling cascade contributing to astrocyte malfunction and SMA pathology. Nevertheless, GATA6, NFjB, and miR-146a may be important players in disease processes and ultimately may be novel therapeutic targets for the treatment of SMA.
Materials and Methods

Pluripotent stem cell culture
We utilized three healthy iPSC control lines previously characterized for full reprogramming (45, 80, 81) , three SMA-iPSC lines derived from individual Type 1 SMA patients (23, 24, 34, 45) . All pluripotent stem cell lines were maintained in feeder-free conditions and cultured on Matrigel (Corning) in Stembrew (Miltenyi Biotech) medium and passaged every 5-7 days. iPSC colonies and the differentiated cells were mycoplasm negative. The use of iPSCs was approved by the Medical College of Wisconsin's Institutional Review Board (PRO25822) and the Human Stem Cell Research Oversight Committee.
Astrocyte differentiation
To generate astrocytes, iPSCs were grown as floating aggregates in Stemline medium (Sigma) supplemented with 100 ng/ml EGF (Miltenyi), 100 ng/ml FGF (Miltenyi), and 5 lg/ml heparin (Sigma) and passaged weekly using a mechanical chopping method (82) for a minimum of 10 weeks following previously established protocols (83, 84) with minor modifications. Passage 10 neurospheres were enzymatically dissociated using TrypLE, and seeded in 6-well plates at 300,000 cells/well on Matrigel-coated wells in Neurobasal with 2% B27. Cells were then grown for 6 weeks in 2% B27 and then replated into 6-well plates for downstream analysis. This protocol removes neurons and generates $90% purified astrocyte cultures.
Motor neuron differentiation
To generate purified motor neuron cultures, embryoid bodies were generated from iPSCs and patterned in the presence of dual SMAD inhibition (SB 431542 and LDN 1931899) followed by treatment with retinoic acid (RA), Chir-99021, smoothened agonist, and DAPT as described (46) . Spinal motor neuron progenitor cells were then dissociated and plated on Matrigel-coated plates for terminal differentiation and maturation in growth factor supplemented medium for 28-42 days in vitro. To generate mixed motor neuron/astrocyte cultures, we followed our previously published protocol in which neurospheres were patterned with RA and purmorphamine (Stemgent) followed by maturation in B27, ascorbic acid, cAMP, BDNF, and GDNF (45, 83) . miR profiling from cell lysates and conditioned medium Conditioned medium from SMA and control iPSC astrocyte cultures was collected at 6 weeks of terminal differentiation. Medium was centrifuged to remove cellular debris and diluted 1:10 in PBS for analysis by the NanoSight LM10 (Malvern). A disposable 1ml syringe was loaded with the diluted medium, and 0.3ml was delivered through capillary tubing to the NanoSight system to pass by the laser light source and quantified by the NanoSight software. Undiluted medium was subjected to further ultracentrifugation to isolate microvesicles containing miRs (85, 86) . Cell pellets from 6-week astrocyte cultures were collected using TrypLE (Thermo Fisher). Vesicles and cell pellets were lysed for total protein and RNA extraction using commercially available isolation kits (Life Technologies). RNA was reverse transcribed using miScript II RT (Qiagen), and the resulting cDNA was used for real-time PCR using the SYBR green human miFinder miRNA PCR Array system (Qiagen, MIHS-001Z) following manufacturer's protocols. Data were imported into the associated online analysis software to determine fold change based on the DDCt method (http://pcrdataanal ysis.sabiosciences.com/mirna/arrayanalysis.php; date last accessed March 21, 2017) . Validation of mature miR-146a expression was performed using a miRCURY LNA Universal RT microRNA cDNA synthesis kit (Exiqon), SYBR Green master mix, Universal RT (Exiqon), LNA PCR primer set for miR-146a-5p (catalog no. 204688), and normalized to miR-103a-3p (catalog no. 304063) (Exiqon, Woburn, MA, USA). Relative abundance was calculated using the DDCt method. Expression of miR-146a downstream targets was performed on cDNA generated from 4-week motor neuron cultures using the RT 2 Profiler PCR Array system (Qiagen, PHAS-6004Z) following manufacturer's protocols. Data were analyzed using the online analysis software (http://pcrdataanalysis.sabiosciences.-com/pcr/arrayanalysis.php; date last accessed May 8, 2017).
miR-146a mimic and inhibition
Cultures of purified motor neurons were treated for 48 h with 40nM mirVana miR-146a oligonucleotide or a random miR sequence (mirVana negative control 1; Ambion) in 1 ll of EndoPorter (Gene Tools, LLC) transfection reagent. Additional sham control cultures were treated with EndoPorter alone. Total ACM was collected from SMA and control astrocytes at 6 weeks of terminal differentiation. 250 ll of SMA or control ACM was added to SMA and control motor neuron cultures in the presence or absence of 40 nM miR-146a inhibitor or 40 nM of a scrambled miR inhibitor for 48 h. Cells were then fixed and stained for ChAT and islet1, and analysed for motor neuron survival.
SMND7 mouse spinal cord miR analysis
All animals were housed and treated in accordance with Animal Care and Use Committee guidelines of the University of Missouri, Columbia, MO, USA. The colony was maintained as heterozygous breeding pairs under specific pathogen free conditions. SMND7 mice (SMND7þ/þ;SMN2þ/þ;Smn À/À ) (49) were genotyped on the day of birth (P0) using standard PCR protocols (JAX Mice Resources) on tail tissue material. P12 het and SMND7 spinal cords (n ¼ 4 each) were dissected and flash frozen in liquid nitrogen. Tissue was stored at À80 C until further use.
Methods for detection of pri-miR-146a were based on previously published methods (87, 88) . Total RNA, including small RNAs, was extracted using the mirVana miRNA isolation kit with phenol (AM1560, Life Technologies Corp, Thermo Fisher Scientific). cDNA was made from 1 lg of total RNA utilizing the SuperScript III Reverse Transcriptase kit (Invitrogen, Carlsbad, CA). Primers used: miR-146a (NR_029558.1) pri-miR-146a-Forward 5' GCCT CATCTGGAGAGTCTGTG, pri-miR-146a-Reverse 5' AACCAGTGT TCTTCAGGTCCG, GAPDH Forward 5' AACTTTGGCATTGTGGA AGG, GAPDH Reverse 5' ACACATTGGGGGTAGGAACA. Quantification of mature miR-146a was performed using a miRCURY LNA Universal RT microRNA cDNA synthesis kit (Exiqon), SYBR Green master mix, Universal RT (Exiqon), LNA PCR primer set for miR-146a-5p (catalog no. 204688), and normalized to miR-103a-3p (catalog no. 304063) (Exiqon, Woburn, MA, USA). Relative qPCR was performed on an Applied Biosystems 7500 fast real-time PCR system and data were analysed by the DDCt method.
Western blot
Whole cell lysates were prepared using 1x Chaps buffer with PMSF and 1x DTT (Cell Signaling). Protein concentration was determined using Bradford Assay (Sigma). Equal amounts of protein were loaded onto 10 or 12% pre-cast Tris-HCl Mini-PROTEAN gels (Bio-Rad) and proteins separated by electrophoresis, then transferred to PVDF membranes (Bio-Rad). Membranes were blocked in Odyssey TBS Blocking Buffer (LI-COR) followed by overnight primary antibody incubation and 30 min secondary antibody incubation. Densitometry was performed with Image Studio quantification software (LI-COR) using REVERT total protein stain (LI-COR). Primary antibodies used were mouse anti-GDNF (Sigma), rabbit anti-GATA6 (Santa Cruz), goat anti-NOTCH1 (Santa Cruz), and rabbit anti-NOTCH2 (Abcam). Secondary antibodies used were anti-goat IRDye 800CW (LI-COR), anti-mouse IRDye 800CW (LI-COR), and antimouse IRDye 680RD (LI-COR).
GATA6 qRT-PCR
RNA was isolated from control and SMA astrocytes using the RNeasy Mini Kit following manufacturer's instructions (Qiagen, 74104) and quantified using a NanoDrop Spectrophotometer. RNA was then treated with RQ1 Rnase-free Dnase (Promega, M6101) and converted to cDNA using the Promega Reverse Transcription System (Promega, A3500). TaqMan qRT-PCR was performed in triplicate using cDNA from three control and three SMA lines. Primers for GATA6 were from a PrimeTime predesigned assay (IDT, Hs.PT.58.3464934). 60s ribosomal protein L (rpl) expression was used for normalization (Thermo Fisher Scientific, Hs04194366_g1).
Immunocytochemistry
Plated cells were fixed in 4% paraformaldehyde (PFA) for 20 min at room temperature and rinsed with PBS. Nonspecific labeling was blocked and the cells permeabilized with 5% normal goat serum and/or 5% normal donkey serum and 0.2% Triton X-100 in PBS for 30 min at room temperature. Cells were rinsed with PBS and then incubated with primary antibodies for 1 h at room temperature or overnight at 4 C. Cells were labeled with the appropriate fluorescently-tagged secondary antibodies. Hoechst nuclear dye was used to label nuclei. Primary antibodies used were mouse anti-Tuj1 (Sigma), rabbit anti-Tuj1 (Covance), mouse anti-SMI-32 (Covance), goat anti-ChAT (Millipore), mouse anti-Islet 1 (Developmental Studies Hybridoma Bank), rabbit anti-GFAP (Dako), mouse anti-GFAP (Cell Signaling), mouse anti-NFjB p65 (L8F6; Cell Signaling), and rabbit antiphospho-NFjB p65 (Ser536, Cell Signaling). Secondary antibodies used were donkey anti-mouse AF488 (Invitrogen), donkey anti-rabbit cy3 (Jackson Immunoresearch), donkey anti-goat AF546 (Invitrogen), donkey anti-rabbit AF488 (Invitrogen), donkey anti-mouse AF647 (Invitrogen), and donkey anti-mouse cy3 (Jackson Immunoresearch).
Calcium imaging
Six-week-old iPSC-derived astrocyte cultures were subjected to ratiometric live-cell calcium imaging using the dual-fluorescent calcium indicator FURA-2AM (Life Technologies) as previously described (22) . Briefly, extracellular normal HEPES (ENH) buffer used throughout the experiment was composed of MilliQ water with 150 mM NaCl, 10 mM HEPES, 8mM glucose, 5.6 mM KCl, 1mM MgCl 2 , and 2 mM CaCl 2 ; pH 7.4; osmolarity 320. iPSCderived astrocytes were loaded with 2.5 ll/ml FURA-2AM for 1 h at room temperature, washed in ENH for 20 min, and mounted on a perfusion chamber on a Nikon Eclipse Ti-U inverted microscope. Solutions were superfused over cells at constant rate of 6mL/min: 2 min ENH to establish baseline measurements, 1-min ENH þ 10 lM ATP, 2-min ENH, 30-s ENH þ 50mM KCl, and 1-min ENH. Videos were taken using an Ando Zyla sCMOS camera and detected and analysed using NIS Elements software (Nikon). Positive response was defined as >20% increase in fluorescence over baseline during time of ATP stimulation.
Immunocytochemical analysis
All immunofluorescence images were analysed using five randomly selected fields per coverslip on an upright Nikon E400 microscope and QCapture camera using equivalent exposure conditions. Samples were blinded and manually counted and measured for positively labeled cells using NIS Elements software.
Statistical analysis
Experimental conditions within each in vitro experiment were performed in triplicate from a minimum of three independent experiments. Data were analysed using the appropriate statistical tests including the Student's t-test and one way ANOVA followed by Tukey's post-hoc analysis of significance. Changes were considered statistically significant when P < 0.05.
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